市场概况

The Whole Exome Sequencing Market is poised for substantial growth, 预计美元增幅 1.43 十亿 2022 兑美元 3.75 十亿 2029. 预计这一增长将由复合年增长率推动 (复合年增长率) 的 14.2% 在预测期内 2023-2029. Exome sequencing is a technique that selectively targets the subset of DNA responsible for encoding proteins, offering a cost-effective screening method for diagnosing genetic disorders. It has gained prominence in the field of drug discovery and development as an alternative to whole-genome sequencing, providing valuable insights into the genetic basis of diseases.

The market growth is driven by expanding applications in clinical diagnosis, particularly in the identification of rare diseases, where whole exome sequencing has proven to be a valuable tool. 此外, ongoing research and development in genomics and next-generation sequencing technologies contribute to the market expansion. The demand for personalized medicine, which relies on precise genetic profiling, also fuels the adoption of whole exome sequencing.

市场细分

The market is segmented based on product, 应用, 最终用户, 和地理.

按产品细分
System
Kits
服务

按应用细分
Second-Generation Sequencing – Sequencing, by Synthesis (SBS), Sequencing, by Hybridization and Ligation (SBL)
Third-Generation Sequencing

Segmentation by End User
Diagnostics
Drug Discovery and Development
Personalized Medicine
其他的

按地理位置细分
北美 – 美国, 加拿大, 墨西哥
欧洲 – 英国, 德国, 法国, 意大利, 西班牙, 和欧洲其他地区
亚太 – 中国, 日本, 印度, 澳大利亚, 韩国, 以及亚太地区其他地区
拉美 – 巴西, 阿根廷, 和拉丁美洲其他地区
中东和非洲 – GCC, 南非, 以及中东和非洲其他地区

Personalized medicine, also known as precision medicine, aims to provide customized therapies based on individual genetic makeup. This approach has gained popularity due to advancements in genetics and understanding of gene influence on health and drug response. Tailoring treatments to patients leads to safer and more effective methods for various conditions. The personalized medicine segment is driven by factors including increasing cancer prevalence, affordability of therapy, fewer side effects, high adoption in developed markets, and development of innovative drugs. Strategic activities like partnerships, 合并, 收购, and product launches by market players are expected to further drive growth.

The North American region dominates the whole exome sequencing market due to factors such as increasing prevalence of genetic and chronic disorders, aging population, demand for personalized medicine, and favorable government initiatives. The burden of infectious diseases, including HIV, further fuels the demand for diagnosis and contributes to market growth. Mergers, 收购, launches, and partnerships among key players also drive growth in North America. With the growing prevalence of infectious diseases and introduction of new products, the North American market is expected to experience significant growth in the forecast period.

竞争格局

The whole exome sequencing market is moderately consolidated, with a limited number of global and regional companies. Key players in the market include Bio-Rad Laboratories Inc., Eurofins Scientific SE, F. 罗氏霍夫曼公司, 照明公司, and Thermo Fisher Scientific Inc. Other notable players include Azenta Inc., BGI Genomics Co. 有限公司, CD Genomics, Geneyx Genomex Ltd, Konica Minolta Inc. (安布里遗传学公司), 珀金埃尔默公司, Psomagen Inc (Macrogen Corp.), 凯杰公司, 和别的. These companies have significant market shares and established reputations.

最新行业发展

In February 2023, Illumina Inc. delivered its first NovaSeqX Plus system to the Broad Institute, providing support for accessing Illumina’s sequencing service, including human whole genome and blended genome/exome products.

In May 2022, the Qatar Genome Program (QGP), a division of the Qatar Foundation (QF), partnered with Thermo Fisher Scientific to advance genomic research and enhance the clinical applications of predictive genomics in Qatar. This partnership aims to extend the benefits of precision medicine to Arab populations.

为什么购买这份报告?

Get a detailed picture of the Global Whole Exome Sequencing Market
Identify segments/areas to invest in over the forecast period in the Global Whole Exome Sequencing Market
了解竞争环境, 市场的领先参与者
Excel 格式的跨场景分析易用性的市场预估
三个月的战略咨询和研究支持
为单用户许可证提供打印验证